Cempra (CEMP -7.9%) bulls among ana

Cempra (CEMP -7.9%) bulls among analysts just lost one of their own. Cowen and Company's Ritu Baral just downgraded the stock to Market Perform citing the lack of clarity with lead product candidate solithromycin.
Since the close 7-6 Ad Comm vote several weeks ago, there have been a rash of downgrades. According to MarketBeat, there are three Buy ratings on the stock and eight Hold/Underweight ratings. Before the Ad Comm, 10 of 11 analysts rated the stock a Buy.

結果 (中文) 2:

Cempra（CEMP -7.9％）分析师们公牛刚刚失去了一个他们自己。考恩和公司的瑞图万方巴拉尔只是将该股评级市场执行援引缺乏清晰度先导候选产品solithromycin的。
由于接近7-6的广告通讯投票数周前，有过降级的皮疹。据MARKETBEAT，也有对股票和八个保持/减持评级3买入评级。广告通讯之前，11 10的分析师评级的股票的买入评级。

結果 (中文) 3:

cempra（7.9 %（CEMP）分析师的一只公牛在迷失自己。Cowen公司’s Just downgraded巴拉尔（股票市场进行citing缺乏清晰的solithromycin引线产品候选人。由于关闭7，6周的广告通讯投票的几个月，就已经在美国的评级下调。根据“市场脉动”，有三个买股票的评级和评级/ underweight扑克。在AD和10，11级，购买股票的分析师。